Clinical Trial Update: QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma [Phase 2]

View source ↗

Summary

Phase 2 study of QUILT-3.011 yeast-brachyury vaccine for chordoma has completed; results were posted on 2024-05-20.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chordoma

Drugs mentioned

• QUILT-3.011 (brachyury-targeted yeast vaccine)

Snippet

Sponsor: NantCell, Inc. | Conditions: Chordoma | Phase 2 | Status: COMPLETED | Results posted: 2024-05-20